Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning

CYD-TDV is the first licensed dengue vaccine for individuals 9–45 (or 60) years of age. Using 12% of the subjects enroled in phase-2b and phase-3 trials for which baseline serostatus was measured, the vaccine-induced protection against virologically confirmed dengue during active surveillance (0–25...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorigatti, I., Donnelly, C. A., Laydon, D. J., Small, R., Jackson, N., Coudeville, L., Ferguson, N. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128884/
https://www.ncbi.nlm.nih.gov/pubmed/30194294
http://dx.doi.org/10.1038/s41467-018-06006-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128884/
https://www.ncbi.nlm.nih.gov/pubmed/30194294
http://dx.doi.org/10.1038/s41467-018-06006-6

Ejemplares similares